Back

A postzygotic GNA13 variant upregulates the RHOA/ROCK pathway and alters melanocyte function in a mosaic skin hypopigmentation syndrome

El Masri, R.; Iannuzzo, A.; Kuentz, P.; Tacine, R.; Vincent, M.; Barbarot, S.; Morice-Picard, F.; Boralevi, F.; Oillarburu, N.; Mazereeuw-Hautier, J.; Duffourd, Y.; Faivre, L.; Sorlin, A.; Vabres, P.; Delon, J.

2024-07-24 dermatology
10.1101/2024.07.24.24310661
Show abstract

The genetic bases of mosaic pigmentation disorders have increasingly been identified, but these conditions remain poorly characterised, and their pathophysiology is unclear. Here, we report in four unrelated patients that a recurrent postzygotic mutation in GNA13 is responsible for a recognizable syndrome with hypomelanosis of Ito associated with developmental anomalies. GNA13 encodes G13, a subunit of {beta}{gamma} heterotrimeric G proteins coupled to specific transmembrane receptors known as G-protein coupled receptors. In-depth functional investigations revealed that this R200K mutation provides a gain of function to G13. Mechanistically, we show that this variant hyperactivates the RHOA/ROCK signalling pathway that consequently increases actin polymerisation and myosin light chains phosphorylation, and promotes melanocytes rounding. Our results also indicate that R200K G13 hyperactivates the YAP signalling pathway. All these changes appear to affect cell migration and adhesion but not the proliferation. Our results suggest that hypopigmentation can result from a defect in melanosome transfer to keratinocytes due to cell shape alterations. These findings highlight the interaction between heterotrimeric G proteins and the RHOA pathway, and their role in melanocyte function.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Nature Communications
based on 483 papers
Top 5%
12.5%
2
The American Journal of Human Genetics
based on 77 papers
Top 2%
7.6%
3
Scientific Reports
based on 701 papers
Top 31%
5.8%
4
PLOS ONE
based on 1737 papers
Top 67%
5.3%
5
eLife
based on 262 papers
Top 4%
5.0%
6
JCI Insight
based on 63 papers
Top 2%
4.5%
7
Human Genomics
based on 13 papers
Top 0.1%
3.0%
8
Nature Medicine
based on 88 papers
Top 3%
2.8%
9
Frontiers in Immunology
based on 140 papers
Top 3%
2.4%
10
Allergy
based on 13 papers
Top 0.8%
2.3%
50% of probability mass above
11
PLOS Neglected Tropical Diseases
based on 166 papers
Top 6%
2.3%
12
Frontiers in Medicine
based on 99 papers
Top 8%
2.3%
13
Brain
based on 69 papers
Top 4%
2.3%
14
BMC Cancer
based on 21 papers
Top 2%
2.3%
15
PLOS Genetics
based on 39 papers
Top 2%
1.8%
16
Journal for ImmunoTherapy of Cancer
based on 14 papers
Top 1%
1.8%
17
EMBO Molecular Medicine
based on 15 papers
Top 0.8%
1.6%
18
Journal of Medical Genetics
based on 22 papers
Top 1%
1.3%
19
Genetics in Medicine
based on 57 papers
Top 4%
1.3%
20
npj Genomic Medicine
based on 18 papers
Top 2%
1.3%
21
Human Genetics
based on 14 papers
Top 0.8%
1.3%
22
Human Genetics and Genomics Advances
based on 39 papers
Top 2%
1.3%
23
Science
based on 46 papers
Top 5%
1.3%
24
Journal of Clinical Immunology
based on 11 papers
Top 0.7%
0.8%
25
PLOS Medicine
based on 95 papers
Top 15%
0.8%
26
Nature Genetics
based on 72 papers
Top 8%
0.8%
27
npj Precision Oncology
based on 14 papers
Top 4%
0.8%
28
Communications Biology
based on 36 papers
Top 5%
0.8%
29
Frontiers in Nutrition
based on 13 papers
Top 2%
0.8%
30
Heliyon
based on 57 papers
Top 14%
0.7%